Labcorp CFO Glenn Eisenberg Announces Plans to Retire
Labcorp (NYSE: LH) announced that Executive Vice President and CFO Glenn Eisenberg will retire, with Julia Wang appointed as the new CFO effective December 2, 2024. Eisenberg will remain as Special Advisor to the CEO through April 2025. During Eisenberg's 10-year tenure, Labcorp doubled its revenues, completed approximately 100 acquisitions worth $11 billion, and returned over $6 billion to shareholders through repurchases and dividends. Wang joins from BeiGene, where she served as CFO and was key in driving business transformations through growth acceleration and operational efficiency.
Labcorp (NYSE: LH) ha annunciato che il Vicepresidente Esecutivo e CFO Glenn Eisenberg si ritirerà, con Julia Wang nominata come nuova CFO a partire dal 2 dicembre 2024. Eisenberg rimarrà come Consigliere Speciale del CEO fino ad aprile 2025. Durante il mandato di 10 anni di Eisenberg, Labcorp ha raddoppiato i suoi ricavi, completato circa 100 acquisizioni per un valore di 11 miliardi di dollari e restituito oltre 6 miliardi di dollari agli azionisti attraverso riacquisti e dividendi. Wang proviene da BeiGene, dove ha ricoperto il ruolo di CFO ed è stata fondamentale nel guidare le trasformazioni aziendali attraverso l'accelerazione della crescita e l'efficienza operativa.
Labcorp (NYSE: LH) anunció que el Vicepresidente Ejecutivo y CFO Glenn Eisenberg se retirará, y Julia Wang ha sido designada como la nueva CFO, efectiva el 2 de diciembre de 2024. Eisenberg permanecerá como Asesor Especial del CEO hasta abril de 2025. Durante el mandato de 10 años de Eisenberg, Labcorp duplicó sus ingresos, completó aproximadamente 100 adquisiciones por un valor de 11 mil millones de dólares y devolvió más de 6 mil millones de dólares a los accionistas a través de recompras y dividendos. Wang se une a la compañía proveniente de BeiGene, donde se desempeñó como CFO y fue clave en impulsar las transformaciones empresariales mediante la aceleración del crecimiento y la eficiencia operativa.
Labcorp (NYSE: LH)는 최고재무책임자(CFO)인 Glenn Eisenberg가 은퇴할 것이라고 발표했으며, Julia Wang이 2024년 12월 2일부터 새로운 CFO로 임명될 예정입니다. Eisenberg는 2025년 4월까지 CEO의 특별 고문으로 남아 있습니다. Eisenberg의 10년 재임 동안 Labcorp는 수익을 두 배로 늘리고, 약 100건의 인수합병을 통해 110억 달러 규모의 거래를 완료했으며, 주식 매입과 배당금을 통해 주주에게 60억 달러 이상을 반환했습니다. Wang은 BeiGene에서 CFO로 재직하며 성장 가속과 운영 효율성을 통해 비즈니스 변화를 주도하는 데 중요한 역할을 했습니다.
Labcorp (NYSE: LH) a annoncé que le vice-président exécutif et CFO Glenn Eisenberg prendra sa retraite, Julia Wang étant nommée nouvelle CFO à compter du 2 décembre 2024. Eisenberg restera conseiller spécial du CEO jusqu'en avril 2025. Au cours du mandat de 10 ans d'Eisenberg, Labcorp a doublé ses revenus, réalisé environ 100 acquisitions d'une valeur de 11 milliards de dollars et restitué plus de 6 milliards de dollars aux actionnaires par le biais de rachats et de dividendes. Wang rejoint l'entreprise en provenance de BeiGene, où elle a occupé le poste de CFO et a joué un rôle clé dans la transformation des entreprises par l'accélération de la croissance et l'efficacité opérationnelle.
Labcorp (NYSE: LH) gab bekannt, dass der Executive Vice President und CFO Glenn Eisenberg in den Ruhestand treten wird, während Julia Wang ab dem 2. Dezember 2024 zur neuen CFO ernannt wird. Eisenberg wird bis April 2025 als besonderer Berater des CEO tätig sein. Während Eisenbergs 10-jähriger Amtszeit hat Labcorp seine Einnahmen verdoppelt, etwa 100 Übernahmen im Wert von 11 Milliarden Dollar abgeschlossen und den Aktionären über 6 Milliarden Dollar durch Aktienrückkäufe und Dividenden zurückgegeben. Wang kommt von BeiGene, wo sie als CFO tätig war und eine Schlüsselrolle bei der Umsetzung von Geschäftsveränderungen durch Wachstumsbeschleunigung und operative Effizienz spielte.
- Company doubled revenues during Eisenberg's tenure
- Completed ~100 acquisitions worth $11 billion
- Returned over $6 billion to shareholders via repurchases and dividends
- Delivered double-digit compound annual total shareholder returns
- None.
Julia Wang Named Chief Financial Officer Beginning December 2, 2024
Ms. Wang brings deep global strategic and financial experience across the diagnostic, pharmaceutical/biotech, medical device and consumer products industries. Most recently, Ms. Wang served as CFO of BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), which she joined in June 2020 as Senior Vice President, Enterprise Optimization and Deputy CFO. While at BeiGene, she was instrumental in driving business transformations through accelerating growth, nurturing innovation and cultivating a culture of sustainable operating efficiencies.
"I want to thank Glenn for a transformative 10 years as Labcorp's CFO," said Schechter. "Under his leadership, Labcorp has more than doubled its revenues from organic growth and acquisitions, while delivering double-digit compound annual total shareholder returns. He has developed a very strong team and has been instrumental in helping us achieve our strategic objectives. Also, during his tenure, Labcorp has completed approximately 100 acquisitions, investing around
Added Schechter, "Julia brings the right mix and diversity of expertise in diagnostics and drug development as well as pharmaceutical and biotech to lead our financial team into Labcorp's next phase of growth. We will benefit from Julia's extensive healthcare and consumer sector experience, strategic insights and operating rigor as we continue to create and unlock value for our shareholders and fulfill our mission to improve health and improve lives."
"I have long admired Labcorp as a trusted brand and am thrilled to join Labcorp as CFO and see clear opportunities to continue executing on our strategy to help deliver better outcomes for patients," said Ms. Wang. "No doubt Labcorp offers a mission-driven, collaborative culture that delivers compelling value for patients, employees and shareholders. I look forward to working with Glenn to ensure a seamless transition and partnering with Adam to position Labcorp to continue to provide excellent value to shareholders and accelerated growth as we enter 2025 with momentum."
About Ms. Julia Wang
Prior to joining BeiGene in 2020, Ms. Wang served as Senior Vice President, Global Business Finance and Corporate Planning at Alexion Pharmaceuticals. Before Alexion, she held leadership positions at Quest Diagnostics, including Vice President of
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-cfo-glenn-eisenberg-announces-plans-to-retire-302309270.html
SOURCE Labcorp Holdings Inc
FAQ
When will Glenn Eisenberg retire as Labcorp (LH) CFO?
Who is the new CFO of Labcorp (LH)?
How many acquisitions did Labcorp (LH) complete under Glenn Eisenberg's leadership?
